Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio (Nasdaq: PASG) announced on July 21, 2022, the granting of inducement awards to new employees, including options to purchase 85,500 shares of common stock at an exercise price of $2.16 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Passage Bio (Nasdaq: PASG) announced on July 21, 2022, the granting of inducement awards to new employees, including options to purchase 85,500 shares of common stock at an exercise price of $2.16 per share. These stock options will vest over four years, with 25% vesting after one year and the remainder in 36 monthly installments, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent in the clinical-stage genetic medicines sector, particularly focused on CNS disorders.
Positive
- Attracts new talent through stock options, fostering employee retention.
- Inducement awards align with Nasdaq compliance, supporting corporate governance.
- Options are at market price, minimizing immediate shareholder dilution.
Negative
- None.
Details
News Market Reaction – PASG
The recorded move for PASG in the trading session of this news was -3.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, July 21, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.
Passage Bio granted options to purchase 85,500 shares of common stock to these employees as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
The shares subject to the Inducement Options will vest over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable grant date, and the remainder vesting in 36 equal monthly installments thereafter, subject to each employee’s continued employment. The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.